leadf
logo-loader
viewBiocept Inc

Biocept prices $6.6M registered direct offering priced at-the-market

It is advancing its liquid biopsy technology called Target Selector that detects cancer biomarkers such as circulating tumor cells

Biocept Inc - Biocept prices $6.6 million registered direct offering priced at-the-market
The $6.6 million, along with $9.2 million from its registered direct offering announced on March 2, and its current cash position will be sufficient to fund operations through to end 2020

Biocept Inc (NASDAQ:BIOC), a provider of liquid biopsy tests, said Thursday that it has entered into a securities purchase agreement with several institutional investors to raise $6.6 million in a registered direct offering priced at-the-market. 

In a statement, the San Diego-based company said that it had struck a securities purchase agreement with several institutional investors for the issuance and sale of 16 million shares at a price of $0.41 per share, for aggregate gross proceeds of approximately $6.6 million, in a registered direct offering priced at-the-market under Nasdaq rules.  

Biocept expects proceeds from the $6.6 million registered direct offering, along with the $9.2 million in gross proceeds from its registered direct offering announced on March 2, and its current cash and cash equivalents, to be sufficient to fund operations through at least December 31, 2020.

READ: Biocept arranges $9.2M financing plan

The announcement comes as the San Diego-based company advances the usage of its flagship Target Selector technology platform.

Target Selector collects and analyzes molecular markers linked to tumors in circulating tumor cells, as well as plasma, to identify cancer mutations. The assays detect lung, breast, gastric, colorectal and prostate cancers as well as melanoma. 

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Quick facts: Biocept Inc

Price: 6.07 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $81.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept reports its liquid biopsy highly accurate in detecting HER2 protein...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the molecular diagnostic assay focused group reported results from a study showing that its Target Selector liquid biopsy was highly accurate in monitoring the HER2 protein alteration in patients with metastatic breast cancer. Nall says...

4 weeks, 1 day ago

2 min read